Valchlor (mechlorethamine gel)

All patients were treated with chlormethine hydrochloride gel in combination with other skin-directed and systemic therapies, including bexarotene, methotrexate, topical steroids, extracorporeal photopheresis, donor lymphocyte infusion and interferon-α (IFN-α) 2a...The combination regimens were generally well tolerated, with associated adverse events being inflammation, pruritus and erythema. This case series reports on the efficacy and safety of chlormethine hydrochloride gel in combination with other topical and systemic therapies in reducing the skin lesion severity in patients with Stage I-IV MF in different real-world settings.

P=N/A, N=840, Recruiting, Leiden University Medical Center | Not yet recruiting --> Recruiting

Six months post-treatment, the patient remained in remission. This case underscores the effectiveness of CG in achieving sustained remission in acral LyP, suggesting its potential as a treatment option for this rare condition.

P=N/A, N=190, Not yet recruiting, Fondazione Italiana Linfomi - ETS

P=N/A, N=840, Not yet recruiting, Leiden University Medical Center

P=N/A, N=70, Recruiting, Columbia University | Trial completion date: Jul 2024 --> Aug 2026 | Trial primary completion date: Jul 2024 --> Aug 2026

P2, N=10, Completed, Soligenix | Recruiting --> Completed

P=N/A, N=40, Recruiting, National and Kapodistrian University of Athens

P2, N=10, Recruiting, Soligenix | Not yet recruiting --> Recruiting

P2, N=10, Not yet recruiting, Soligenix

In this exploratory, open-label, deep phenotyping trial a total of 21 early-stage (IA – IIA) MF patients were treated with chlormethine gel 160μg/g QD for 16 weeks...We show for the first time the feasibility of suction blister fluid analysis to investigate TME in MF patients. These results suggest that CD8+HLA-DR+ cytotoxic and regulatory T-lymphocytes have a prominent role in disease improvement with chlormethine therapy in MF.

Materials & In this exploratory, open-label, deep phenotyping trial a total of 21 early-stage (IA – IIA) MF patients were treated with chlormethine gel 160µg/g QD for 16 weeks... We show for the first time the feasibility of suction blister fluid analysis to investigate TME in MF patients. These results suggest that CD8+HLA-DR+ cytotoxic and regulatory T-lymphocytes have a prominent role in disease improvement with chlormethine therapy in MF.